MX2010004682A - Metodo de supresion de hormonas en humanos. - Google Patents
Metodo de supresion de hormonas en humanos.Info
- Publication number
- MX2010004682A MX2010004682A MX2010004682A MX2010004682A MX2010004682A MX 2010004682 A MX2010004682 A MX 2010004682A MX 2010004682 A MX2010004682 A MX 2010004682A MX 2010004682 A MX2010004682 A MX 2010004682A MX 2010004682 A MX2010004682 A MX 2010004682A
- Authority
- MX
- Mexico
- Prior art keywords
- humans
- hormone
- inhibitor
- halogen
- methyl
- Prior art date
Links
- 229940088597 hormone Drugs 0.000 title abstract 2
- 239000005556 hormone Substances 0.000 title abstract 2
- 230000001629 suppression Effects 0.000 title 1
- 229940122387 Glycine transporter 1 inhibitor Drugs 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- WDPFQABQVGJEBZ-MAKOZQESSA-N Bothermon Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 WDPFQABQVGJEBZ-MAKOZQESSA-N 0.000 abstract 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 abstract 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 abstract 1
- 206010066364 Hypersexuality Diseases 0.000 abstract 1
- 102000009151 Luteinizing Hormone Human genes 0.000 abstract 1
- 108010073521 Luteinizing Hormone Proteins 0.000 abstract 1
- 239000003433 contraceptive agent Substances 0.000 abstract 1
- 230000002254 contraceptive effect Effects 0.000 abstract 1
- 229940028334 follicle stimulating hormone Drugs 0.000 abstract 1
- 229940040129 luteinizing hormone Drugs 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a un inhibidor del transportador-1 de glicina que tiene la fórmula (I), en donde X es de 1 a 3 substituyentes seleccionados de H, halógeno, metilo, metoxi, trifluorometilo y trifluorometoxi e Y es de 1 a 3 substituyentes seleccionados de H, metilo y halógeno o una sal farmacéuticamente aceptable del mismo para utilizarse en un tratamiento en los humanos para suprimir el nivel de una o más hormonas seleccionadas de hormona luteinizante, hormona estimulante de folículo, estradiol y testosterona. La presente invención se refiere además a dicho inhibidor del transportador-1 de glicina como parte de un régimen anticonceptivo o como un tratamiento para la hipersexualidad.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07120100 | 2007-11-06 | ||
| PCT/EP2008/064914 WO2009059961A2 (en) | 2007-11-06 | 2008-11-04 | A method of hormone suppression in humans |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010004682A true MX2010004682A (es) | 2010-05-19 |
Family
ID=40259200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010004682A MX2010004682A (es) | 2007-11-06 | 2008-11-04 | Metodo de supresion de hormonas en humanos. |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110118353A1 (es) |
| EP (1) | EP2207542A2 (es) |
| JP (1) | JP2011502974A (es) |
| CA (1) | CA2703497A1 (es) |
| MX (1) | MX2010004682A (es) |
| WO (1) | WO2009059961A2 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2917735B1 (fr) | 2007-06-21 | 2009-09-04 | Sanofi Aventis Sa | Nouveaux indazoles substitutes, leur preparation et leur utilisation en therapeutique |
| CN107936076B (zh) | 2011-09-08 | 2021-10-15 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物、及其用途 |
| WO2014160480A1 (en) | 2013-03-13 | 2014-10-02 | Sage Therapeutics, Inc. | Neuroactive steroids and methods of use thereof |
| EP4306114A1 (en) | 2014-06-18 | 2024-01-17 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| AU2015330906A1 (en) * | 2014-10-07 | 2017-04-27 | Sage Therapeutics, Inc. | Neuroactive compounds and methods of use thereof |
| US11117924B2 (en) | 2015-07-06 | 2021-09-14 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| EP4316591A3 (en) | 2015-07-06 | 2024-04-24 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| IL305404A (en) | 2015-07-06 | 2023-10-01 | Sage Therapeutics Inc | Oxysterols and methods of using them |
| BR112018070123A2 (pt) | 2016-04-01 | 2019-02-05 | Sage Therapeutics Inc | oxiesterós e métodos de uso dos mesmos |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| CA3029900A1 (en) | 2016-07-07 | 2018-01-11 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| EP3519422B1 (en) | 2016-09-30 | 2022-08-31 | Sage Therapeutics, Inc. | C7 substituted oxysterols and these compounds for use as nmda modulators |
| AU2017345399B2 (en) | 2016-10-18 | 2022-02-24 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| CN115181153A (zh) | 2016-10-18 | 2022-10-14 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW555757B (en) * | 1998-07-31 | 2003-10-01 | Akzo Nobel Nv | Aminomethylcarboxylic acid derivatives |
| RU2007130941A (ru) * | 2005-01-14 | 2009-02-20 | Н.В. Органон (Nl) | Ингибиторы повторного поглощения глицина для лечения зависимости от наркотиков и алкоголя |
| GB0607398D0 (en) * | 2006-04-12 | 2006-05-24 | Glaxo Group Ltd | Compounds |
-
2008
- 2008-11-04 JP JP2010531544A patent/JP2011502974A/ja active Pending
- 2008-11-04 WO PCT/EP2008/064914 patent/WO2009059961A2/en active Application Filing
- 2008-11-04 US US12/740,716 patent/US20110118353A1/en not_active Abandoned
- 2008-11-04 CA CA2703497A patent/CA2703497A1/en not_active Abandoned
- 2008-11-04 EP EP08847867A patent/EP2207542A2/en not_active Withdrawn
- 2008-11-04 MX MX2010004682A patent/MX2010004682A/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011502974A (ja) | 2011-01-27 |
| WO2009059961A3 (en) | 2010-01-21 |
| US20110118353A1 (en) | 2011-05-19 |
| EP2207542A2 (en) | 2010-07-21 |
| CA2703497A1 (en) | 2009-05-14 |
| WO2009059961A2 (en) | 2009-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010004682A (es) | Metodo de supresion de hormonas en humanos. | |
| UA105014C2 (uk) | Інгібітор p38 map-кінази | |
| MY159958A (en) | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors | |
| EA030735B9 (ru) | ПРИМЕНЕНИЕ sGC СТИМУЛЯТОРОВ ДЛЯ ЛЕЧЕНИЯ СИСТЕМНОГО СКЛЕРОЗА (SSc) | |
| IL182218A0 (en) | Preparation and use of biphenyl-4-yl-carbonylamino and derivatives for the treatment of obesity | |
| UA100979C2 (ru) | Применение пиридопиримидиноновых ингибиторов pi3k альфа для лечения рака | |
| EA200970933A1 (ru) | Способы лечения или профилактики рвоты с помощью агентов, усиливающих секрецию гормона роста | |
| MX2013003634A (es) | Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales. | |
| SG179418A1 (en) | Inhibitors of the hedgehog pathway | |
| WO2008142055A3 (en) | Antiviral agents | |
| MX2013002927A (es) | Inhibidores del virus de la hepatitis c. | |
| HK1145839A1 (en) | N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors | |
| WO2009138186A3 (de) | SEQUENTIELLE VERARBEITUNG VON 20,20,21,21-PENTAFLUOR-17-HYDROXY-11β-[4-(HYDROXYACETYL) PHENYL] -19-NOR-17α-PREGNA-4,9-DIEN-3-ON UND EINEM ODER MEHREREN GESTAGENEN ZUR BEHANDLUNG GYNÄKOLOGISCHER ERKRANKUNGEN | |
| MX2014003180A (es) | Metodos para tratar vhc. | |
| WO2011150190A3 (en) | Hcv inhibitor compounds and methods of use thereof | |
| EA200800766A1 (ru) | Ингибиторы pi3k для лечения эндометриоза | |
| IS7315A (is) | Útskipt díketópíperasín sem oxýtósínmótlyf | |
| WO2008053270A3 (en) | Use of an egfr antagonist for the treatment of glomerolonephritis | |
| SI2201002T1 (sl) | Antagonisti 5-ht7 receptorja | |
| TW200612962A (en) | Estriol and estetrol prodrugs | |
| TW200738232A (en) | Use of vanilloid receptor-1 antagonists for the prevention and treatment of glaucoma | |
| PT1984005E (pt) | Uso de complexos de gálio para o tratamento de melanomas | |
| MX2013003551A (es) | Formas en estado solido de un potente inhibidor del vch. | |
| UA96736C2 (ru) | Ингибиторы pi3k для лечения эндометриоза | |
| NZ595482A (en) | Method of treating osteoporosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights | ||
| FG | Grant or registration |